Prospector
Profile
2-6-001
|
| |
| Royaltech Corp. |
NAICS |
541710 |
| 1855 Talleyrand, Suite 203A
Brossard, Quebec, Canada J4W 2Y9 |
Description |
Biotechnology |
| (514) 867-9829 |
Employees |
0 |
|
Revenue |
(mil) |
0.0000 |
| |
Income |
(mil) |
-0.0989 |
| |
Assets |
(mil) |
0.0660 |
| |
Liability |
(mil) |
0.0080 |
| |
(for the year ended 2007-09-30) |
| |
|
Category:
Audit Concerns
|
| |
|
Event:
Manning Elliott LLP expressed substantial doubt on Royaltech Corp.'s ability to continue as a going concern after auditing the Company's financial statements for the years ended September 30, 2007 and 2006. The auditor notes that the Company has not generated revenue and has accumulated losses since inception. The Company posted a net loss of $98,996 for the year ended September 30, 2007, slightly higher than the $87,623 net loss reported in the prior year. At September 30, 2007, the Company's balance sheet showed $66,660 in total assets, $8,032 in total liabilities and $58,628 in total stockholders' equity.
|
| |
|
Intellectual Property:
The Company has obtained the non-exclusive right to manufacture and market four clinical diagnostic techniques/kits which were developed by Mr. Kang Zhang after years of research and development. These techniques/kits have been approved by the Chinese government after a series of clinical testing and meet the regulations of various Chinese State agencies. The Company also has the first right to manufacture and market any future products that are currently under development. [SEC Filing 10-KSB 01-15-08]
|
| |
|
Description:
Royaltech Corp. is engaged in developing, manufacturing and marketing of biotech products that are applied in medical diagnosis.
|
| |
|
Officers:
Chenxi Shi (Pres. & CEO); Chun Xu (VP); Louis H. Ladouceur (Corporate Development and Public Affair Officer); Kang Zhang (Biomedical Technology Officer); John B. Richardson (Medical Officer); Edward Beshlian (Mktg. Officer)
|
| |
|
Auditor:
Manning Elliott LLP
|
| |
|
Securities:
Common Stock-Symbol RYTE.OB; OTC BB; 17,252,425 common shares outstanding as of January 11, 2008.
|
| |
| |
| |
| return to main page |
